The Heart Failure Revascularisation Trial (HEART): Rationale, Design and Methodology

JGF Cleland, Nick Freemantle, SG Ball, Robert Bonser, PG Camici, S Chattopadhyay, D Dutka, Joanne Eastaugh

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

BACKGROUND: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. AIMS: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. METHODS: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction
Original languageEnglish
Pages (from-to)295-303
Number of pages9
JournalEuropean Journal of Heart Failure
Volume5
Issue number3
DOIs
Publication statusPublished - 1 Jun 2003

Keywords

  • revascularisation
  • HEART study
  • left ventricular systolic dysfunction
  • heart failure

Fingerprint

Dive into the research topics of 'The Heart Failure Revascularisation Trial (HEART): Rationale, Design and Methodology'. Together they form a unique fingerprint.

Cite this